A new oil-based oral formulation of prostate cancer drug abiraterone acetate could enable a smaller dose of the drug to be effective and reduce possible side effects, a study has shown.
List view / Grid view
Filter the results
A new potential platform for drug delivery has been created by researchers using attentuate diptheria toxin, which can enter cells and escape the endosome.
Researchers have used a specific chemical signal released from a major bacterial pathogen to improve the activity of fluconazole against Candida biofilms.
An international team of researchers has used nanoparticles to deliver a drug – one that previously failed in clinical trials for pain – into specific compartments of nerve cells, dramatically increasing its ability to treat pain in mice and rats. Nikki Withers spoke to Nigel Bunnett to hear more about…
While medical professionals fight COVID-19 on the front line, small biotech businesses face a new uphill battle – maintaining research continuity for non-COVID-19 life-changing therapeutics.
By attaching cyclic peptides to modified liposomes, researchers have created a potential form of drug delivery able to cross the blood-brain barrier.
The developers of the novel formulation, containing the cannabinoids CBDV and CBGA, now intend to test the clinical safety and efficacy of its anti-cancer activity.
Experiments testing the artificial cardiac patch in pigs and rats showed the patch can reduce scarring and improve cardiac function after a heart attack.
The coalition has been formed to find R&D solutions for low- and middle-income countries to limit the impact of the COVID-19 pandemic in areas with fragile healthcare systems.
Researchers have created a microneedle array that successfully delivered a COVID-19 vaccine to mice, allowing them to produce antibodies against the virus.
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.
Following the selection of a COVID-19 vaccine lead, Johnson & Johnson (J&J) aims to begin clinical trials in humans later this year while also scaling up its manufacturing facilities.
Novel particles could be incorporated into topical creams to treat dermatological conditions without systemic exposure to drugs.
Using AAV-based technology to deliver mAbs in a Phase I trial, researchers report that participants successfully developed antibodies against HIV.
Researchers have shown that Nilvadipine can slow the rate of cognitive decline in very early- and early-stage Alzheimer’s patients and have received funding to develop improved versions.